PharmaTher Provides Product Pipeline Updates and Anticipated Milestones for Q4-2021 and 2022

PharmaTher Provides Product Pipeline Updates and Anticipated Milestones for Q4-2021 and 2022 - RICH TV LIVE - SEPTEMBER 13, 2021 - 10 clinical sites selected to participate in the FDA Phase 2 clinical study evaluating ketamine for the treatment of Parkinson’s Disease Initiated investigational new drug (IND) application to proceed to a Phase 2 clinical study for KETABET to treat depression Completed Phase 2 clinical study protocol for ketamine to treat ALS for IND submission to the FDA Near completion of research programs to advance novel microneedle patches for the delivery of psychedelics Selected CDMO to develop and supply proprietary ketamine products for FDA Phase 3 clinical studies and commercialization Positioned ketamine focused product pipeline for potential Phase 3 clinical studies and commercial supply in 2022 PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage...